Sylvamo (NYSE: SLVM) director Stan Askren to resign for health reasons

Rhea-AI Filing Summary

Sylvamo Corporation reports that director Stan Askren has notified the company of his intent to resign from its Board of Directors for health reasons, effective September 1, 2025. The company states that his resignation is not due to any disagreement with or concerning Sylvamo. The Board expresses its appreciation for his service and contributions since the company’s spinoff in 2021.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

Sylvamo Corp false 0001856485 0001856485 2025-08-19 2025-08-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 19, 2025

SYLVAMO CORPORATION

(Exact name of registrant as specified in its charter)

Commission file number 001-40718

Delaware		86-2596371
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification No.)

6077 Primacy Parkway, Memphis, Tennessee		38119
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (901) 519-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $1 per share par value		SLVM		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 19, 2025, Stan Askren provided notice of his intent to resign from the Board of Directors (the “Board”) of Sylvamo Corporation for health reasons, effective September 1, 2025. His resignation is not due to any disagreement with or concerning Sylvamo. The Board expresses its appreciation to Mr. Askren for his service and contributions as a Board member since our spinoff in 2021.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 22, 2025				Sylvamo Corporation
				By:		/s/ Matthew Barron
				Name:		Matthew Barron
				Title:		Senior Vice President and Chief Administrative and Legal Officer

FAQ

What did Sylvamo (SLVM) disclose in this 8-K filing?

Sylvamo disclosed that director Stan Askren has given notice of his intent to resign from the Board of Directors for health reasons, effective September 1, 2025.

Why is Sylvamo director Stan Askren resigning from the Board?

The filing states that Stan Askren is resigning from Sylvamo’s Board of Directors for health reasons.

Is Stan Askren’s resignation from Sylvamo due to a disagreement with the company?

No. The filing explicitly states that his resignation is not due to any disagreement with or concerning Sylvamo.

When will Stan Askren’s resignation from the Sylvamo Board become effective?

According to the filing, Stan Askren’s resignation from the Board of Directors will be effective on September 1, 2025.

How long has Stan Askren served on Sylvamo’s Board of Directors?

The filing notes that Stan Askren has served as a Board member since Sylvamo’s spinoff in 2021.

Did Sylvamo’s Board comment on Stan Askren’s departure?

Yes. The Board expressed its appreciation to Mr. Askren for his service and contributions as a Board member since the 2021 spinoff.